Study of serum S100P level and its relation to diabetic peripheral neuropathy in patients with type-2 diabetes | ||||
| Egyptian Journal of Obesity, Diabetes and Endocrinology | ||||
| Volume 7, Issue 3, December 2022 PDF (593.26 K) | ||||
| DOI: 10.4103/ejode.ejode_20_21 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Talaat A. Aaty; Mohamed Rizk; Rehab Elnemr; Aya Ali; Reem Fathalla | ||||
| Abstract | ||||
| Background S100P, a binder of receptors for advanced-glycation end products, is an established biomarker of many types of cancer. However, data regarding its role in diabetes and diabetic peripheral neuropathy (DPN) are unclear. Aim The aim of this work was to study the relationship between serum S100P and DPN in patients with type-2 diabetes mellitus (T2DM). Participants and methods This cross-sectional study included a total of 90 subjects divided into three groups: 30 patients with T2DM complicated with peripheral neuropathy (group A), 30 patients with T2DM without peripheral neuropathy (group B), and 30 subjects as healthy-control group (group C). All patients with T2DM were assessed for peripheral neuropathy using Michigan neuropathy screening instruments and nerve-conduction study was done to diagnose subclinical neuropathy. Serum S100P was assessed by enzyme-linked immunosorbent assay technique. Results Mean serum S100P levels in group A and group B were significantly lower compared with group C (<0.001 for both comparisons). However, there was no significant difference in mean serum S100P levels between groups A and B (=0.394). Conclusion Serum S100P is significantly low in T2DM with no significant association with DPN. | ||||
| Keywords | ||||
| biomarkers; Diabetic peripheral neuropathy; S100P; Type-2 diabetes mellitus | ||||
|
Statistics Article View: 11 PDF Download: 11 |
||||
